COVALENT LINKERS IN ANTIBODY-DRUG CONJUGATES AND METHODS OF MAKING AND USING THE SAME

(19)

(11)

EP 3 334 462 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	20.04.2022 Bulletin 2022/16

(45)	Mention of the grant of the patent:
	19.01.2022 Bulletin 2022/03

(21)	Application number: 16837634.1

(22)	Date of filing: 15.08.2016

(51)

International Patent Classification (IPC):

A61K 47/50^(2017.01)
A61K 31/5383^(2006.01)
A61P 35/00^(2006.01)
C07K 16/32^(2006.01)

A61K 47/06^(2006.01)
A61K 31/426^(2006.01)
A61K 47/68^(2017.01)

(52)	Cooperative Patent Classification (CPC):
	A61K 47/6803; A61K 47/6855; A61K 47/6869; A61K 47/6889; C07K 16/32; A61P 35/00

(86)	International application number:
	PCT/US2016/046987

(87)	International publication number:
	WO 2017/031034 (23.02.2017 Gazette 2017/08)

(54)	COVALENT LINKERS IN ANTIBODY-DRUG CONJUGATES AND METHODS OF MAKING AND USING THE SAME KOVALENTE LINKER IN ANTIKÖRPER-WIRKSTOFF-KONJUGATEN UND VERFAHREN ZUR HERSTELLUNG UND VERWENDUNG DAVON LIEURS COVALENTS DANS DES CONJUGUÉS ANTICORPS-MÉDICAMENT ET LEURS PROCÉDÉS DE PRODUCTION ET D'UTILISATION

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

14.08.2015 US 201562205121 P

(43)	Date of publication of application:
	20.06.2018 Bulletin 2018/25

(60)	Divisional application:
	21206552.8 / 3981433

(73)	Proprietor: RemeGen Biosciences, Inc.
	Fremont, CA 94538 (US)

(72)	Inventors:
	HUANG, Chang Jiang Los Angeles, CA 90064 (US) FANG, Jianmin Palo Alto, CA 94306 (US) YE, Hui Shandong 264006 (CN) ZHANG, Lezhi Shandong 264006 (CN)

(74)	Representative: Icosa
	83 avenue Denfert-Rochereau 75014 Paris 75014 Paris (FR)

(56)

References cited: :

WO-A1-2013/085925
WO-A1-2015/004400
WO-A2-2016/064749
CN-A- 103 933 575

WO-A1-2013/085925
WO-A2-2015/187596
CN-A- 103 933 575
US-A1- 2003 215 395

YAO, X. ET AL.: 'A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity' BREAST CANCER RESEARCH AND TREATMENT vol. 153, no. 1, 08 August 2015, pages 123 - 133, XP055370764
QIN, M. ET AL.: 'Click conjugation of peptide to hydrogel nanoparticles for tumor-targeted drug delivery' BIOMACROMOLECULES vol. 15, no. 10, 13 October 2014, pages 3728 - 3734, XP055370767
J. Guenther ET AL: "Synthesis, Immobilization, MAS and HR-MAS NMR of a New Chelate Phosphine Linker System, and Catalysis by Rhodium Adducts Thereof", Advanced Synthesis & Catalysis, vol. 353, no. 2-3, 11 February 2011 (2011-02-11), pages 443-460, XP055681607, DE ISSN: 1615-4150, DOI: 10.1002/adsc.201000585

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).